

CITATION REPORT

List of articles citing

Renal function in gout: long-term treatment effects of febuxo

DOI: 10.1097/rhu.ob013e318204aab4

Journal of Clinical Rheumatology, 2011, 17, 7-13.

Source: <https://exaly.com/paper-pdf/50710626/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
98	Efficacy and safety of febuxostat in patients with hyperuricemia and gout. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2011 , 3, 245-53	3.8	25
97	Tophaceous gout and renal insufficiency: a new solution for an old therapeutic dilemma. <i>Case Reports in Medicine</i> , 2011 , 2011, 397646	0.7	6
96	Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2011 , 30, 1011-7	1.4	5
95	Hyperuricemia, gout and the kidney. <i>Current Opinion in Rheumatology</i> , 2012 , 24, 127-31	5.3	44
94	The efficacy and safety of febuxostat for urate lowering in gout patients ≥5 years of age. <i>BMC Geriatrics</i> , 2012 , 12, 11	4.1	26
93	Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2012 , 42, 166-78	5.3	32
92	Reduced glomerular function and prevalence of gout: NHANES 2009-10. <i>PLoS ONE</i> , 2012 , 7, e50046	3.7	76
91	Asymptomatic Hyperuricemia: Cardiovascular and Renal Implications. 2012 , 226-238		5
90	[Gout as a systemic disease. Manifestations, complications and comorbidities of hyperuricaemia]. <i>Zeitschrift Fur Rheumatologie</i> , 2012 , 71, 224-30	1.9	10
89	African American patients with gout: efficacy and safety of febuxostat vs allopurinol. <i>BMC Musculoskeletal Disorders</i> , 2012 , 13, 15	2.8	15
88	Urate reduction and renal preservation: what is the evidence?. <i>Current Rheumatology Reports</i> , 2013 , 15, 386	4.9	5
87	Acute renal failure caused by hyperuremic acidemia in ABO-incompatible kidney transplant maintained with cyclosporine and high-dose mizoribine: a case report. <i>Transplantation Proceedings</i> , 2013 , 45, 2815-8	1.1	3
86	Serum uric acid and cardio-renal diseases. <i>Current Medical Research and Opinion</i> , 2013 , 29 Suppl 3, 25-31	2.5	6
85	Epidemiology of gout. 2013 , 6-23		
84	Uric Acid - key ingredient in the recipe for cardiorenal metabolic syndrome. <i>CardioRenal Medicine</i> , 2013 , 3, 208-220	2.8	114
83	Preservation of renal function during gout treatment with febuxostat: a quantitative study. <i>Postgraduate Medicine</i> , 2013 , 125, 106-14	3.7	40
82	Serum urate and incidence of kidney disease among veterans with gout. <i>Journal of Rheumatology</i> , 2013 , 40, 1166-72	4.1	22

81	Novel drugs and intervention strategies for the treatment of chronic kidney disease. <i>British Journal of Clinical Pharmacology</i> , 2013 , 76, 536-50	3.8	32
80	Gout and its comorbidities: implications for therapy. <i>Rheumatology</i> , 2013 , 52, 34-44	3.9	63
79	Changes in serum uric acid have a reciprocal effect on eGFR change: a 10-year follow-up study of community-based screening in Okinawa, Japan. <i>Hypertension Research</i> , 2013 , 36, 650-4	4.7	34
78	[The cutting-edge of medicine; role of hyperuricemia in cardiorenal syndrome]. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2013 , 102, 1484-91	0	
77	The Urate-lowering Efficacy and Safety of Febuxostat in Korean Patients with Gout. <i>Journal of Rheumatic Diseases</i> , 2013 , 20, 223	1.2	2
76	Four-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men. <i>Journal of Korean Medical Science</i> , 2014 , 29, 1077-81	4.7	30
75	Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29, 406-13	4.3	148
74	Anti-inflammatory and antipyretic analgesics and drugs used in gout. <i>Side Effects of Drugs Annual</i> , 2014 , 35, 197-215	0.2	
73	Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials. <i>BMC Research Notes</i> , 2014 , 7, 54	2.3	18
72	[Update gout: what has changed in diagnosis and treatment?]. <i>MMW Fortschritte Der Medizin</i> , 2014 , 156, 58-62; quiz 63	0	
71	Efficacy and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in kidney transplant recipients. <i>Transplantation Proceedings</i> , 2014 , 46, 511-3 ^{1.1}		16
70	The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study. <i>Trials</i> , 2014 , 15, 26	2.8	52
69	Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease. <i>Renal Failure</i> , 2014 , 36, 225-31	2.9	26
68	Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction. <i>Hypertension Research</i> , 2014 , 37, 919-25	4.7	51
67	Urate-lowering therapy: current options and future prospects for elderly patients with gout. <i>Drugs and Aging</i> , 2014 , 31, 777-86	4.7	13
66	Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems. <i>Clinical and Experimental Hypertension</i> , 2014 , 36, 433-40	2.2	5
65	Improving cardiovascular and renal outcomes in gout: what should we target?. <i>Nature Reviews Rheumatology</i> , 2014 , 10, 654-61	8.1	117
64	Febuxostat: drug review and update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014 , 10, 747-58.5		21

63	Febuxostat for hyperuricemia in patients with advanced chronic kidney disease. <i>Drug Target Insights</i> , 2014 , 8, 39-43	3.4	24
62	[Kidney diseases and metabolic disorders--basics and applications required for general physicians. Topics: IV. Uric acid metabolic disorder (relationship between hyperuricemia and CKD-CVD)]. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2015 , 104, 931-7	0	
61	Challenges and opportunities in the development of therapeutics for chronic kidney disease. <i>Translational Research</i> , 2015 , 165, 482-7	11	
60	Uric acid as a biomarker and a therapeutic target in diabetes. <i>Canadian Journal of Diabetes</i> , 2015 , 39, 239-46	2.1	77
59	Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout. <i>Drugs</i> , 2015 , 75, 427-38	12.1	44
58	Detrimental role of hyperuricemia on the cardio-reno-vascular system. <i>Current Medical Research and Opinion</i> , 2015 , 31 Suppl 2, 21-6	2.5	11
57	Effect of Febuxostat, a Xanthine Oxidase Inhibitor, on Cardiovascular Risk in Hyperuricemic Patients with Hypertension: A Prospective, Open-label, Pilot Study. <i>Clinical Drug Investigation</i> , 2015 , 35, 823-31	3.2	29
56	Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. <i>American Journal of Physiology - Renal Physiology</i> , 2015 , 308, F77-83	4.3	105
55	Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2035-43	9.5	69
54	Plasma uric acid effects on glomerular haemodynamic profile of patients with uncomplicated Type 1 diabetes mellitus. <i>Diabetic Medicine</i> , 2016 , 33, 1102-11	3.5	13
53	Comparison of the Renoprotective Effect of Febuxostat for the Treatment of Hyperuricemia between Patients with and without Type 2 Diabetes Mellitus: A Retrospective Observational Study. <i>Internal Medicine</i> , 2016 , 55, 3247-3256	1.1	7
52	[Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)]. <i>Zeitschrift Fur Rheumatologie</i> , 2016 , 75 Suppl 2, 11-60	1.9	20
51	Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study. <i>Scandinavian Journal of Rheumatology</i> , 2016 , 45, 304-11	1.9	24
50	Febuxostat for the chronic management of hyperuricemia in patients with gout. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 665-73	3.8	19
49	The safety of treatment options available for gout. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 429-436	4.1	14
48	Renal and Vascular Effects of Uric Acid Lowering in Normouricemic Patients With Uncomplicated Type 1 Diabetes. <i>Diabetes</i> , 2017 , 66, 1939-1949	0.9	20
47	Treatment of asymptomatic hyperuricemia in chronic kidney disease: A new target in an old enemy - A review. <i>Journal of Advanced Research</i> , 2017 , 8, 551-554	13	14
46	Management of Gout and Hyperuricemia in CKD. <i>American Journal of Kidney Diseases</i> , 2017 , 70, 422-439	7.4	69

45	The role of urate-lowering treatment on cardiovascular and renal disease: evidence from CARES, FAST, ALL-HEART, and FEATHER studies. <i>Current Medical Research and Opinion</i> , 2017 , 33, 27-32	2.5	9
44	Serum uric acid and acute kidney injury: A mini review. <i>Journal of Advanced Research</i> , 2017 , 8, 529-536	13	60
43	Etiology and Pathogenesis of Hyperuricemia and Gout. 2017 , 1597-1619.e6		2
42	Effects of uric acid-lowering therapy in patients with chronic kidney disease: A meta-analysis. <i>PLoS ONE</i> , 2017 , 12, e0187550	3.7	49
41	Does Altered Uric Acid Metabolism Contribute to Diabetic Kidney Disease Pathophysiology?. <i>Current Diabetes Reports</i> , 2018 , 18, 18	5.6	9
40	Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2018 , 71, 851-865	7.4	181
39	Design and Rationale for the Veterans Affairs "Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat" Trial. <i>Contemporary Clinical Trials</i> , 2018 , 68, 102-108	2.3	7
38	Recent pharmacological advances in the management of gout. <i>Rheumatology</i> , 2018 , 57, 951-958	3.9	9
37	Chronic Kidney Disease. 2018 , 411-421.e11		0
36	Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. <i>American Journal of Kidney Diseases</i> , 2018 , 72, 798-810	7.4	135
35	Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study. <i>Arthritis Research and Therapy</i> , 2018 , 20, 99	5.7	14
34	Improving adherence to gout therapy: an expert review. <i>Therapeutics and Clinical Risk Management</i> , 2018 , 14, 793-802	2.9	12
33	Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat. <i>Pharmaceuticals</i> , 2018 , 11,	5.2	29
32	Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. <i>Arthritis and Rheumatology</i> , 2019 , 71, 143-153	9.5	8
31	Uric acid and progression of chronic kidney disease. <i>Pediatric Nephrology</i> , 2019 , 34, 801-809	3.2	13
30	The Role of a "Treat-to-Target" Approach in the Long-Term Renal Outcomes of Patients with Gout. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	
29	Metabolomics analysis elucidates unique influences on purine / pyrimidine metabolism by xanthine oxidoreductase inhibitors in a rat model of renal ischemia-reperfusion injury. <i>Molecular Medicine</i> , 2019 , 25, 40	6.2	11
28	Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients. <i>Arthritis Research and Therapy</i> , 2019 , 21, 210	5.7	3

27	Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial). <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2020 , 26, 202-208	1.8	2
26	Hyperuricemia and Hypertension, Coronary Artery Disease, Kidney Disease: From Concept to Practice. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	11
25	Hyperuricemia Predisposes to the Onset of Diabetes via Promoting Pancreatic β Cell Death in Uricase-Deficient Male Mice. <i>Diabetes</i> , 2020 , 69, 1149-1163	0.9	17
24	Mangiferin Ameliorates Hyperuricemic Nephropathy Which Is Associated With Downregulation of AQP2 and Increased Urinary Uric Acid Excretion. <i>Frontiers in Pharmacology</i> , 2020 , 11, 49	5.6	13
23	Pegloticase treatment of chronic refractory gout: Update on efficacy and safety. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, S31-S38	5.3	7
22	Effect of Curcumin on Serum Urate in Asymptomatic Hyperuricemia: A Randomized Placebo-Controlled Trial. <i>Journal of Dietary Supplements</i> , 2021 , 18, 248-260	2.3	4
21	The Association between Hyperuricemia and Mortality in Patients with Acute Kidney Injury. <i>Advances in Clinical Medicine</i> , 2021 , 11, 1695-1702	0	
20	Management and Cure of Gouty Arthritis. <i>Medical Clinics of North America</i> , 2021 , 105, 297-310	7	3
19	Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	20
18	Hyperuricemia in Renal patients: Treat or not to treat. <i>Archives of Clinical Nephrology</i> , 2021 , 050-056	0	
17	Etiology and Pathogenesis of Hyperuricemia and Gout. 2013 , 1533-1553.e5		5
16	Kidney Disease and Gout: The Role of the Innate Immune System. <i>The Open Urology & Nephrology Journal</i> , 2016 , 9, 12-21	0.2	1
15	Management of Acute and Chronic Gout –The Nephrology Perspective. <i>The Open Urology & Nephrology Journal</i> , 2016 , 9, 7-11	0.2	
14	Gout. 2017 , 179-195		
13	The current treatment strategy for gouty arthritis. <i>Sovremennaya Revmatologiya</i> , 2018 , 12, 70-75	0.7	
12	Current Possibilities in the Correction of Hyperuricemia in Patients with Urolithiasis and Uric Acid Hypercrystallization. <i>Health of Man</i> , 2019 , 70-74	0.1	
11	Progression of Chronic Kidney Disease and Nephroprotection in Children. 2021 , 1-22		
10	Management and Cure of Gouty Arthritis.. <i>Rheumatic Disease Clinics of North America</i> , 2022 , 48, 479-492	2.4	0

- 9 Management of gout in the primary care setting.. *Malaysian Family Physician*, **2022**, 17, 2-9 0.5 ○
- 8 Image_1.jpeg. **2020**,
- 7 Image_2.tif. **2020**,
- 6 Febuxostat as an effective drug of choice for urate-lowering therapy for gout (case report). **2022**, 137-144
- 5 Progression of Chronic Kidney Disease and Nephroprotection in Children. **2022**, 1679-1700 ○
- 4 Xanthine Oxidase Inhibitory Activity and Chemical Composition of Pistacia chinensis Leaf Essential Oil. **2022**, 14, 1982 1
- 3 The Relevance of Hyperuricaemia. 100-104 ○
- 2 Progression of Chronic Kidney Disease and Nephroprotective Therapy. **2023**, 1483-1515 ○
- 1 Uric Acid in Chronic Kidney Disease: A Clinical Appraisal. 78-83 ○